We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Campylobacter sialyltransferase gene polymorphism directs clinical features of Guillain–Barré syndrome.
- Authors
Yuki, Nobuhiro
- Abstract
Progress has been made in Guillain–Barré syndrome, a post-infectious autoimmune neuropathy, especially on identifying Campylobacter jejuni genes responsible for the development and determinant of clinical features. C. jejuni strains carrying a sialyltransferase gene ( cst-II), which is essential for the biosynthesis of ganglioside-like lipo-oligosaccharides (LOSs), are associated with the development of Guillain–Barré syndrome. The C. jejuni sialyltransferase (Cst-II) consists of 291 amino acids, and the 51st determines its enzymatic activity. Strains with cst-II (Thr51) expressed GM1-like and GD1a-like LOS, whereas strains with cst-II (Asn51) expressed GT1a-like and GD1c-like LOS. Patients infected with the cst-II (Thr51) strains had anti-GM1 or anti-GD1a IgG antibodies, and showed limb weakness. Patients infected with the cst-II (Asn51) strains had anti-GQ1b IgG antibodies, and showed ophthalmoplegia and ataxia. The cst-II gene is responsible for the development of Guillain–Barré and Fisher syndromes, and the polymorphism (Thr/Asn51) determines which syndrome develops after C. jejuni enteritis.
- Subjects
CAMPYLOBACTER; GENETIC polymorphisms; GANGLIOSIDES; GUILLAIN-Barre syndrome; NEUROPATHY
- Publication
Journal of Neurochemistry, 2007, Vol 103, p150
- ISSN
0022-3042
- Publication type
Article
- DOI
10.1111/j.1471-4159.2007.04707.x